Vincristine

Generic Name: Vincristine

Brand Names: Marqibo, Vincasar

Drug Type: Small Molecule

Chemical Formula: C_₄₆H_₅₆N_₄O_₁₀

CAS Number: 57-22-7

Unique Ingredient Identifier: 5J49Q6B70F

Background: Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Indication: Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma

Associated Therapies: -

Clinical Trials

Chidamide Plus R-CHOP in Elderly DLBCL

Phase 2

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Chidamide

First Posted Date: 2016-04-28

Last Posted Date: 2017-11-14

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 49

Registration Number: NCT02753647

Locations: 🇨🇳
Shanghai Ruijin Hospital, Shanghai, Shanghai, China

Reduced Chemotherapy in Low Risk DLBCL

Phase 4

Active, not recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Epirubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2016-04-27

Last Posted Date: 2022-12-05

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 290

Registration Number: NCT02752815

Locations: 🇨🇳
Shanghai Ruijin Hospital, Shanghai, Shanghai, China

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

Phase 2

Active, not recruiting

Conditions: Medulloblastoma

Interventions: Drug: Cisplatin
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Drug: Lomustine
Procedure: Magnetic Resonance Imaging
Radiation: Radiation Therapy
Drug: Vincristine
Drug: Vincristine Sulfate

First Posted Date: 2016-03-31

Last Posted Date: 2024-10-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 45

Registration Number: NCT02724579

Locations: 🇺🇸
Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States
🇺🇸
Tufts Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 194 locations

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Phase 3

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Ibrutinib
Drug: Rituximab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Drug: Vincristine
Drug: Idarubicin
Drug: Dexamethasone

First Posted Date: 2016-03-09

Last Posted Date: 2022-12-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 72

Registration Number: NCT02703272

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Phase 2

Completed

Conditions: Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Pleomorphic Xanthoastrocytoma
Angiocentric Glioma
Giant Cell Astrocytoma
Anaplastic Pleomorphic Xanthoastrocytoma
Oligodendroglioma, Childhood
Glioblastoma
Astrocytoma
Pilocytic Astrocytoma

Interventions: Drug: Dabrafenib
Drug: Carboplatin
Drug: trametinib
Drug: Vincristine

First Posted Date: 2016-02-17

Last Posted Date: 2023-12-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 151

Registration Number: NCT02684058

Locations: 🇺🇸
Ann and Robert H Lurie Childrens Hospital of Chicago ., Chicago, Illinois, United States
🇺🇸
Texas Children s Hospital Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States

and more 8 locations

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

Phase 1

Completed

Conditions: Neoplasm Metastasis

Interventions: Drug: Olaratumab
Drug: Doxorubicin
Drug: Ifosfamide
Drug: Vincristine
Drug: Irinotecan

First Posted Date: 2016-02-09

Last Posted Date: 2020-05-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 68

Registration Number: NCT02677116

Locations: 🇺🇸
St Jude Childrens Research Hospital, Memphis, Tennessee, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Childrens Hospital of Los Angeles, Los Angeles, California, United States

and more 18 locations